cefpiramide and Urinary-Tract-Infections

Topics: Animals; Bacteria; Cephalosporins; Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; Humans; Respiratory Tract Infections; Tissue Distribution; Urinary Tract Infections

Topics: Animals; Bacteria; Cephalosporins; Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; Humans; Respiratory Tract Infections; Tissue Distribution; Urinary Tract Infections

The therapeutic efficacy and safety of Cefpiramide (CPM, SM-1652) at a 2 g/day dose were objectively compared with those of Cefsulodin (CFS) at a 2 g/day dose in patients with chronic complicated urinary tract infections (UTI) by P. aeruginosa in a double-blind study at 46 institutions in Japan. The results are as follows: The therapeutic efficacy was analyzed in 254 patients (136 cases administered CPM and 118 cases administered CFS) after excluding 20 cases as drop-out. Among 254 cases, the number of patients with infection of P. aeruginosa was 190 cases (100 cases administered CPM and 90 cases administered CFS), while that with infection of organisms other than P. aeruginosa was 64 cases (36 cases administered CPM and 28 cases administered CFS). By the administration of a 2 g/day dose for 5 days, the overall clinical effective rate of CPM was significantly higher than that of CFS in total patients. When the patients were classified into 2 groups with respect to causative organisms (P. aeruginosa and others), the clinical effective rate of CPM in patients with infections of P. aeruginosa was significantly higher than that of CFS, while the clinical effective rate of CPM in patients with infection of other organisms than P. aeruginosa was the same as that of CFS. As to the bacteriological effect on bacteriuria, the eradication rate of CPM was significantly higher than that of CFS not only against all causative organisms but also against P. aeruginosa. The rate of replacement by S. faecalis was significantly higher in the CFS-treated group than in the CPM-treated group. The same result was obtained on the rate of replacement by other organisms. The MIC values of CPM for isolated organisms before drug administration were lower than those of CFS. The incidence rates of side effects and the abnormal findings of clinical laboratory tests were the same for the CPM- and CFS-treated groups. From the results, it was concluded that CPM is a useful drug for the treatment of patients with chronic complicated urinary tract infections caused by P. aeruginosa.

Topics: Adult; Aged; Cefsulodin; Cephalosporins; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pseudomonas Infections; Urinary Tract Infections

Topics: Adolescent; Adult; Aged; Cefmetazole; Cephalosporins; Cephamycins; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Urinary Tract Infections

Twenty-one pediatric patients with moderate or severe infections were treated with cefpiramide (CPM). The drug was given intravenously in a dose of 10 approximately 52.3 mg per kg at 8 approximately 12 hourly interval. All 7 patients with urinary tract infection, 4 with bacterial enteritis and 4 out of 7 patients with lower respiratory tract infections responded satisfactory, but 2 patients with either Serratia marcescens septicemia or H. influenzae meningitis not responded to treatment. Over all response rate was 71.4 percent. There was no change in test of liver and renal function. CPM appears to be effective and well-tolerated antibiotics for the treatment of pediatric patients with various infections.

Topics: Age Factors; Bacterial Infections; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Enteritis; Female; Humans; Infant; Injections, Intravenous; Male; Respiratory Tract Infections; Urinary Tract Infections

Clinical effects of cefpiramide (CPM) on 10 respiratory tract infections were excellent in 9 and poor in 1, and those on 3 urinary tract infections were excellent in 3. Although CPM is considered to be excreted mainly into bile, it was suggested that the excretion rate of CPM at doses of 10 approximately 20 mg/kg into urine is good enough. Antibacterial activity of CPM was considered to be almost the same as that of cefmetazole and cefoperazone. As to side effects, weak diarrhea was observed in 2 cases. This should be considered when CPM is given to children because of its main excretion route to bile duct.

Topics: Adolescent; Age Factors; Bacteria; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Infant; Male; Respiratory Tract Infections; Urinary Tract Infections

Clinical studies of cefpiramide (CPM), a newly developed cephem antibiotic, were performed in 10 children with respiratory tract infection in 4 cases, acute enteritis in 2 cases and urinary tract infection in 4 cases aged from 2 months to 10 years and 4 months. CPM was intravenously given to patients at doses of 16 approximately 58 mg/kg/day divided into 3 times for 3 approximately 22 days. Clinical effects were excellent in 6, good in 3 and fair in 1. Bacteriologically, 3 strains of pathogenic organisms (Salmonella C2 group, E. coli and S. faecalis) isolated from the patients were eradicated with the treatment of CPM. No side effect was observed.

Topics: Age Factors; Bacteria; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Drug Resistance, Microbial; Enteritis; Female; Humans; Infant; Male; Respiratory Tract Infections; Urinary Tract Infections

Fundamental and clinical trials were carried out with cefpiramide (CPM) in pediatric infections. Results were as follows. CPM has a broad spectrum of activity against both Gram-positive and -negative microorganisms, including Pseudomonas. Half-lives of CPM were more prolonged than any others that have ever been reported on cephalosporin derivatives. The mean half-lives in the blood after infection were 4.76 hours and 4.14 hours, when the doses were 10 mg/kg and 20 mg/kg, respectively. The average recovery rates in the urine between 0 and 8 hours were 17.1% and 24.7%, when the intravenous doses were 10 mg/kg and 20 mg/kg, respectively. Thirty-two pediatric patients received CPM in doses ranging from 31.9 to 88.2 mg/kg divided mainly 2 times a day. They were respiratory tract infection in 23, urinary tract infection in 8, and SSSS in 1. The rate of satisfactory clinical response was 90.6%. Clinical side effect observed were mild diarrhea in 7 cases. Slight elevation of GOT and GPT were observed in 3 cases. All were considered to be minor.

Topics: Adolescent; Age Factors; Bacteria; Bacterial Infections; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Male; Respiratory Tract Infections; Urinary Tract Infections

The authors treated a total of 23 patients (15 were outpatients, 8 were hospitalized), employing an injectable preparation of cefpiramide (CPM) a new antibiotic of the cephems. Included in this total were 10 cases of acute infectious diseases of skin and soft tissues, 5 cases of acute localized peritonitis, 5 cases of acute urinary tract infection and 3 cases of acute and subacute cholecystitis. To 15 cases of outpatients, CPM in a dose of 500 mg were given by intramuscular injection once a day, and to 8 cases of hospitalized patients were given 500 mg of CPM by intramuscular injection twice a day. The duration were 3 to 15 days. The clinical efficacy obtained was excellent in 4 cases, good in 17 cases, and fair in 2 cases. In no case was CPM found to be completely ineffective. Clinical adverse effect was not recognized. Therefore, CPM will be a useful drug when used for chemotherapy of acute or subacute infectious diseases on surgical field following intramuscular administration.

Topics: Acute Disease; Adult; Aged; Bacterial Infections; Cephalosporins; Cholecystitis; Drug Evaluation; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Peritonitis; Postoperative Complications; Skin Diseases, Infectious; Urinary Tract Infections